Cosyntropin vs Macimorelin
Head-to-head comparison of Cosyntropin (Cosyntropin (ACTH 1-24)) and Macimorelin (Macimorelin acetate (AEZS-130)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Cosyntropin | Macimorelin |
|---|---|---|
| Category | Pain Management | Growth Hormone |
| Full Name | Cosyntropin (ACTH 1-24) | Macimorelin acetate (AEZS-130) |
| Molecular Weight | 2933.3 Da | N/A |
| Half-Life | ~10 min | about 4-6 hours |
| Amino Acids | 24 | N/A |
| Typical Dose | 0.25 mg IV/IM diagnostic dose|off-label headache protocols vary | 0.5 mg/kg single oral dose |
| Route | IV|IM | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 61 | 120 |
| Research Status | Clinical research | Clinical |
Cosyntropin Benefits
- ✓refractory migraine
- ✓anti-inflammatory signaling
- ✓headache rescue research
Macimorelin Benefits
- ✓diagnostic GH stimulation
- ✓single oral dose
- ✓rapid measurable GH response
- ✓high clinical utility
Cosyntropin Dosing
0.25 mg IV/IM|1 mg IV/IM
Macimorelin Dosing
0.5 mg/kg orally as a single dose|fasted testing conditions|serial GH sampling after administration
Cosyntropin Side Effects
- ⚠flushing
- ⚠nausea
Macimorelin Side Effects
- ⚠dysgeusia or taste disturbance
- ⚠nausea
- ⚠headache
Research Overview
Cosyntropin
Cosyntropin is not a standard pain drug, but it appears in headache literature because ACTH analogs can help some patients with difficult migraine attacks. The analgesic rationale is partly tied to steroidogenic and anti-inflammatory effects.
Macimorelin
Macimorelin has been validated in clinical testing as an oral alternative to injectable GH stimulation tests. Its short-term use makes it a useful translational tool for evaluating pituitary GH reserve.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.